Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 4:20 PM ET. The event will be held virtually, and a live webcast can be accessed on the Company’s website under the 'Investors' section. Additionally, the webcast will be available for replay for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, including QINLOCK, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST).

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10^th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005276/en/

FAQ

When is Deciphera Pharmaceuticals' fireside chat at the SVB Leerink Healthcare Conference?

The fireside chat will take place on February 25, 2021, at 4:20 PM ET.

How can I watch the Deciphera Pharmaceuticals fireside chat?

You can watch the live webcast on Deciphera's 'Events and Presentations' page in the 'Investors' section of their website.

What is QINLOCK from Deciphera Pharmaceuticals?

QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST).

Is QINLOCK approved in countries other than the U.S.?

Yes, QINLOCK is also approved for fourth-line GIST treatment in Canada and Australia.

Will the webcast of the Deciphera Pharmaceuticals event be available later?

Yes, the webcast will be archived and available for replay for 90 days after the presentation.